Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > A couple of "stupid" questions

<< Previous

Bullboard Posts

Next >>

Comment by RjM2018on Apr 23, 2021 8:11pm

157 Views

Post# 33060313

RE:A couple of "stupid" questions

P3 further reduces risk. Although we showed statistically signifcant effiacy and safety with 250mg & 200mg doses, the 150mg dose wasn't powered for statistical significance. There was a very clear signal that the 150mg dose could be stat. sig. efficacious. Phase 3 trial is an adaptive design, in that they will study lower doses (like, 200mg, 150mg, 125/100mg) to find the lowest effective dose for go-to-market over 6 weeks vs 2 weeks for phase 2b.

Risks is that because the duration of treatment is 3x longer, AEs could arise...

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing